RAPID MICRO BIOSYSTEMS INC RPID
CLASS A COM · Common Stock · CUSIP 75340L104
- SectorTechnology
- IndustryLaboratory Analytical Instruments
- HeadquartersLexington, MA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.66.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 54 |
| Q4 2022 | 43 |
| Q1 2023 | 32 |
| Q2 2023 | 25 |
| Q3 2023 | 24 |
| Q4 2023 | 27 |
| Q1 2024 | 24 |
| Q2 2024 | 22 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 16 | 28 |
| Q1 2023 | 7 | 24 |
| Q2 2023 | 6 | 15 |
| Q3 2023 | 5 | 10 |
| Q4 2023 | 12 | 6 |
| Q1 2024 | 7 | 11 |
| Q2 2024 | 6 | 10 |
Biggest buyers
| TWO SIGMA SECURITIES, LLC | New | +11.0k |
| GEODE CAPITAL MANAGEMENT, LLC | Added | +9.4k |
| RENAISSANCE TECHNOLOGIES LLC | Added | +8.6k |
| Tower Research Capital LLC (TRC) | Added | +2.7k |
| ROYAL BANK OF CANADA | Added | +382 |
| BANK OF AMERICA CORP /DE/ | Added | +81 |
Biggest sellers
| BlackRock Inc. | Reduced | -371.2k |
| GLENVIEW CAPITAL MANAGEMENT, LLC | Reduced | -117.5k |
| JPMORGAN CHASE & CO | Reduced | -97.8k |
| MORGAN STANLEY | Reduced | -20.2k |
| GOLDMAN SACHS GROUP INC | Sold out | -18.6k |
| Virtu Financial LLC | Sold out | -10.9k |
| MILLENNIUM MANAGEMENT LLC | Reduced | -7.2k |
| WELLS FARGO & COMPANY/MN | Sold out | -157 |
| UBS Group AG | Reduced | -148 |
| NORTHERN TRUST CORP | Reduced | -100 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Bain Capital Life Sciences Fund, L.P. 13G · exempt (held before listing) filed 2026-08-14 | 16.8% |
| Longitude Capital Partners II, LLC 13G · exempt (held before listing) filed 2026-05-15 | 8.6% |
| ARMISTICE CAPITAL, LLC 13G · institution new · filed 2026-08-14 | 7.3% |
Spignesi Robert G. Jr.
13D · may seek influence
new · filed 2025-08-19
Stated purposeThe information set forth or incorporated by reference in Items 3 and 6 of this Statement is incorporated by reference into this Item 4. The Reporting Person intends to continuously review his investment in the Issuer and may in the future determine (1) to acquire additional securities of the Issuer, through open market purchases, private agreements or otherwise, (2) to dispose of all or a portion of the securities of the Issuer owned by him or (3) to take any other available course of action. Notwithstanding anything contained herein, the Reporting Person specifically reserves the right to change his intention with respect to any or all of such matters. In reaching any decision as to his course of action (as well as to the specific elements thereof), the Reporting Person currently expect… Full filing |
6.3% |
| Endeavour Medtech Growth II LP 13G · passive investor filed 2026-02-13 | 5.7% |
Insider purchases and sales in Q2 2024
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 0 | — | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 1 | $18.2k | 0 | — | — |
| Q3 2023 | 2 | $60.6k | 0 | — | — |
| Q4 2023 | 0 | — | 0 | — | — |
| Q1 2024 | 0 | — | 0 | — | — |
| Q2 2024 | 0 | — | 0 | — | — |
None reported in Q2 2024.
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC 0.61% of their portfolio | 8.4m $5.6m | Unchanged |
| KENNEDY LEWIS MANAGEMENT LP 14.06% of their portfolio | 4.9m $3.3m | Unchanged |
| GLENVIEW CAPITAL MANAGEMENT, LLC 0.02% of their portfolio | 1.2m $792.5k | Reduced -117.5k |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 1.1m $757.6k | Reduced -97.8k |
| ABG-WTT Global Life Science Capital Partners GP Ltd 2.29% of their portfolio | 1.0m $685.3k | Unchanged |
| VANGUARD GROUP INC 0.00% of their portfolio | 728.5k $480.8k | Unchanged |
| BlackRock Inc. 0.00% of their portfolio | 648.5k $428.0k | Reduced -371.2k |
| Advent International, L.P. 0.01% of their portfolio | 577.8k $381.3k | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 170.6k $112.6k | Added +9.4k |
| RENAISSANCE TECHNOLOGIES LLC 0.00% of their portfolio | 66.0k $43.6k | Added +8.6k |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 59.0k $38.9k | Reduced -7.2k |
| STATE STREET CORP 0.00% of their portfolio | 26.1k $17.2k | Unchanged |
| NORTHERN TRUST CORP 0.00% of their portfolio | 15.6k $10.3k | Reduced -100 |
| TWO SIGMA SECURITIES, LLC 0.00% of their portfolio | 11.0k $7.2k | New |
| MORGAN STANLEY 0.00% of their portfolio | 10.1k $6.7k | Reduced -20.2k |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 8.3k $5.5k | Added +2.7k |
| RESOURCES MANAGEMENT CORP /CT/ /ADV 0.00% of their portfolio | 500 $0 | Unchanged |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 442 $0 | Added +382 |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 164 $108 | Added +81 |
| UBS Group AG 0.00% of their portfolio | 98 $65 | Reduced -148 |
| Qube Research & Technologies Ltd 0.00% of their portfolio | 4 $2 | Unchanged |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |